Amgen’s Growth Story Relies Mainly On Continuing Plot Lines
Forecasts Mid-Single-Digit Revenue CAGR Through 2030
Executive Summary
Established brands Repatha and Otezla, new launches Lumakras and Tezspire, and the Amjevita-led biosimilars portfolio will provide most of the company’s growth through the end of this decade.
You may also be interested in...
Supreme Court May Consider Ruling Invalidating Amgen’s Repatha Patents
Court asks Solicitor General to weigh in on petition challenging Federal Circuit’s standard for determining patent enablement in Amgen’s dispute with PCSK9 inhibitor rivals Sanofi and Regeneron. GlaxoSmithKline, Biogen, Bristol-Myers Squibb, and Merck filed briefs in support of Amgen.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Scrip asks what 2022 holds for deal-making; Pfizer looks for transactions to add to its top line; Sanofi unworried about JAK threat to Dupixent; what information do healthcare professionals want from pharma; and Amgen looks to its established brands for growth.
Amgen Revenue Boosted By COVID-19 Manufacturing, Flat To Down Without It
The company reported $6.8bn in fourth quarter revenue, missing analyst consensus of $6.9bn even with revenue from supplying Lilly’s COVID-19 antibodies. Enbrel and Aimovig fell by double digits.